Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2012

Open Access 01-07-2012 | Preclinical Study

MUTYH gene variants and breast cancer in a Dutch case–control study

Authors: Astrid A. Out, Marijke Wasielewski, Petra E. A. Huijts, Ivonne J. H. M. van Minderhout, Jeanine J. Houwing-Duistermaat, Carli M. J. Tops, Maartje Nielsen, Caroline Seynaeve, Juul T. Wijnen, Martijn H. Breuning, Christi J. van Asperen, Mieke Schutte, Frederik J. Hes, Peter Devilee

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Abstract

The MUTYH gene is involved in base excision repair. MUTYH mutations predispose to recessively inherited colorectal polyposis and cancer. Here, we evaluate an association with breast cancer (BC), following up our previous finding of an elevated BC frequency among Dutch bi-allelic MUTYH mutation carriers. A case–control study was performed comparing 1,469 incident BC patients (ORIGO cohort), 471 individuals displaying features suggesting a genetic predisposition for BC, but without a detectable BRCA1 or BRCA2 mutation (BRCAx cohort), and 1,666 controls. First, for 303 consecutive patients diagnosed before age 55 years and/or with multiple primary breast tumors, the MUTYH coding region and flanking introns were sequenced. The remaining subjects were genotyped for five coding variants, p.Tyr179Cys, p.Arg309Cys, p.Gly396Asp, p.Pro405Leu, and p.Ser515Phe, and four tagging SNPs, c.37-2487G>T, p.Val22Met, c.504+35G>A, and p.Gln338His. No bi-allelic pathogenic MUTYH mutations were identified. The pathogenic variant p.Gly396Asp and the variant of uncertain significance p.Arg309Cys occurred twice as frequently in BRCAx subjects as compared to incident BC patients and controls (p = 0.13 and p = 0.15, respectively). The likely benign variant p.Val22Met occurred less frequently in patients from the incident BC (p = 0.03) and BRCAx groups (p = 0.11), respectively, as compared to the controls. Minor allele genotypes of several MUTYH variants showed trends towards association with lobular BC histology. This extensive case–control study could not confirm previously reported associations of MUTYH variants with BC, although it was too small to exclude subtle effects on BC susceptibility.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cheadle JP, Sampson JR (2007) MUTYH-associated polyposis—from defect in base excision repair to clinical genetic testing. DNA Repair (Amst) 6:274–279CrossRef Cheadle JP, Sampson JR (2007) MUTYH-associated polyposis—from defect in base excision repair to clinical genetic testing. DNA Repair (Amst) 6:274–279CrossRef
2.
go back to reference Jones S, Emmerson P, Maynard J et al (2002) Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C → T:A mutations. Hum Mol Genet 11:2961–2967PubMedCrossRef Jones S, Emmerson P, Maynard J et al (2002) Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C → T:A mutations. Hum Mol Genet 11:2961–2967PubMedCrossRef
3.
go back to reference Jones S, Lambert S, Williams GT, Best JM, Sampson JR, Cheadle JP (2004) Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. Br J Cancer 90:1591–1593PubMedCrossRef Jones S, Lambert S, Williams GT, Best JM, Sampson JR, Cheadle JP (2004) Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. Br J Cancer 90:1591–1593PubMedCrossRef
4.
go back to reference Nielsen M, Franken PF, Reinards TH et al (2005) Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 42:e54PubMedCrossRef Nielsen M, Franken PF, Reinards TH et al (2005) Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 42:e54PubMedCrossRef
5.
go back to reference Theodoratou E, Campbell H, Tenesa A et al (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 103:1875–1884PubMedCrossRef Theodoratou E, Campbell H, Tenesa A et al (2010) A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 103:1875–1884PubMedCrossRef
6.
go back to reference Vogt S, Jones N, Christian D et al (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985PubMedCrossRef Vogt S, Jones N, Christian D et al (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985PubMedCrossRef
7.
go back to reference Wasielewski M, Out AA, Vermeulen J et al (2010) Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer. Breast Cancer Res Treat 124:635–641 Wasielewski M, Out AA, Vermeulen J et al (2010) Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer. Breast Cancer Res Treat 124:635–641
8.
go back to reference Wang X, Szabo C, Qian C et al (2008) Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res 68:971–975PubMedCrossRef Wang X, Szabo C, Qian C et al (2008) Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res 68:971–975PubMedCrossRef
9.
go back to reference Li D, Zhang W, Zhu J et al (2001) Oxidative DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic lyase in human breast cancer. Mol Carcinog 31:214–223PubMedCrossRef Li D, Zhang W, Zhu J et al (2001) Oxidative DNA damage and 8-hydroxy-2-deoxyguanosine DNA glycosylase/apurinic lyase in human breast cancer. Mol Carcinog 31:214–223PubMedCrossRef
10.
go back to reference Soliman AS, Vulimiri SV, Kleiner HE et al (2004) High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt. Int J Environ Health Res 14:121–134PubMedCrossRef Soliman AS, Vulimiri SV, Kleiner HE et al (2004) High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt. Int J Environ Health Res 14:121–134PubMedCrossRef
11.
go back to reference Dziaman T, Huzarski T, Gackowski D et al (2009) Elevated level of 8-oxo-7,8-dihydro-2′-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. Int J Cancer 125:2209–2213PubMedCrossRef Dziaman T, Huzarski T, Gackowski D et al (2009) Elevated level of 8-oxo-7,8-dihydro-2′-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. Int J Cancer 125:2209–2213PubMedCrossRef
12.
go back to reference Le Page F, Randrianarison V, Marot D et al (2000) BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 60:5548–5552PubMed Le Page F, Randrianarison V, Marot D et al (2000) BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 60:5548–5552PubMed
13.
go back to reference Furuuchi K, Tada M, Yamada H et al (2000) Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 156:1997–2005PubMedCrossRef Furuuchi K, Tada M, Yamada H et al (2000) Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 156:1997–2005PubMedCrossRef
14.
go back to reference Sieber OM, Howarth KM, Thirlwell C et al (2004) Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice. Cancer Res 64:8876–8881PubMedCrossRef Sieber OM, Howarth KM, Thirlwell C et al (2004) Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice. Cancer Res 64:8876–8881PubMedCrossRef
15.
go back to reference Radpour R, Fan AX, Kohler C, Holzgreve W, Zhong XY (2009) Current understanding of mitochondrial DNA in breast cancer. Breast J 15:505–509PubMedCrossRef Radpour R, Fan AX, Kohler C, Holzgreve W, Zhong XY (2009) Current understanding of mitochondrial DNA in breast cancer. Breast J 15:505–509PubMedCrossRef
16.
go back to reference Wasielewski M, Riaz M, Vermeulen J et al (2009) Association of rare MSH6 variants with familial breast cancer. Breast Cancer Res Treat 123:315–320 Wasielewski M, Riaz M, Vermeulen J et al (2009) Association of rare MSH6 variants with familial breast cancer. Breast Cancer Res Treat 123:315–320
17.
go back to reference Didraga MA, van Beers EH, Joosse SA et al (2011) A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Res Treat 130:425–436 Didraga MA, van Beers EH, Joosse SA et al (2011) A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Res Treat 130:425–436
18.
go back to reference Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59PubMedCrossRef Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59PubMedCrossRef
19.
go back to reference Huijts PE, Vreeswijk MP, Kroeze-Jansema KH et al (2007) Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 9:R78PubMedCrossRef Huijts PE, Vreeswijk MP, Kroeze-Jansema KH et al (2007) Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 9:R78PubMedCrossRef
20.
go back to reference Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96:11–15PubMedCrossRef Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96:11–15PubMedCrossRef
21.
go back to reference Out AA, van Minderhout IJ, Goeman JJ et al (2009) Deep sequencing to reveal new variants in pooled DNA samples. Hum Mutat 30:1703–1712PubMedCrossRef Out AA, van Minderhout IJ, Goeman JJ et al (2009) Deep sequencing to reveal new variants in pooled DNA samples. Hum Mutat 30:1703–1712PubMedCrossRef
22.
go back to reference Out AA, Tops CM, Nielsen M et al (2010) Leiden Open Variation Database of the MUTYH gene. Hum Mutat 31:1205–1215PubMedCrossRef Out AA, Tops CM, Nielsen M et al (2010) Leiden Open Variation Database of the MUTYH gene. Hum Mutat 31:1205–1215PubMedCrossRef
23.
go back to reference Barrett JC(2009) Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb.ip71 Barrett JC(2009) Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb.ip71
24.
go back to reference Aretz S, Uhlhaas S, Goergens H et al (2006) MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 119:807–814PubMedCrossRef Aretz S, Uhlhaas S, Goergens H et al (2006) MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 119:807–814PubMedCrossRef
25.
go back to reference Peterlongo P, Mitra N, Sanchez de Abajo A et al (2006) Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis 27:2243–2249PubMedCrossRef Peterlongo P, Mitra N, Sanchez de Abajo A et al (2006) Increased frequency of disease-causing MYH mutations in colon cancer families. Carcinogenesis 27:2243–2249PubMedCrossRef
26.
go back to reference Cleary SP, Cotterchio M, Jenkins MA et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136:1251–1260PubMedCrossRef Cleary SP, Cotterchio M, Jenkins MA et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136:1251–1260PubMedCrossRef
27.
go back to reference Halford SE, Rowan AJ, Lipton L et al (2003) Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol 162:1545–1548PubMedCrossRef Halford SE, Rowan AJ, Lipton L et al (2003) Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol 162:1545–1548PubMedCrossRef
28.
go back to reference Goto M, Shinmura K, Nakabeppu Y et al (2010) Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant proteins found in patients with colorectal polyposis and cancer. Hum Mutat 31:E1861–E1874PubMedCrossRef Goto M, Shinmura K, Nakabeppu Y et al (2010) Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant proteins found in patients with colorectal polyposis and cancer. Hum Mutat 31:E1861–E1874PubMedCrossRef
29.
go back to reference Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O (2011) MutYH mutation carriers have increased breast cancer risk. Cancer. doi:10.1002/cncr.26506 Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O (2011) MutYH mutation carriers have increased breast cancer risk. Cancer. doi:10.​1002/​cncr.​26506
30.
go back to reference Beiner ME, Zhang WW, Zhang S, Gallinger S, Sun P, Narod SA (2009) Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Breast Cancer Res Treat 114:575–578PubMedCrossRef Beiner ME, Zhang WW, Zhang S, Gallinger S, Sun P, Narod SA (2009) Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Breast Cancer Res Treat 114:575–578PubMedCrossRef
31.
go back to reference Zhang Y, Newcomb PA, Egan KM et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358PubMedCrossRef Zhang Y, Newcomb PA, Egan KM et al (2006) Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:353–358PubMedCrossRef
32.
go back to reference Conde J, Silva SN, Azevedo AP et al (2009) Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study. BMC Cancer 9:344PubMedCrossRef Conde J, Silva SN, Azevedo AP et al (2009) Association of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study. BMC Cancer 9:344PubMedCrossRef
33.
go back to reference Linn SC, van ‘t Veer LJ (2009) Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 45(Suppl 1):11–26PubMedCrossRef Linn SC, van ‘t Veer LJ (2009) Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur J Cancer 45(Suppl 1):11–26PubMedCrossRef
34.
go back to reference Broeks A, Schmidt MK, Sherman ME et al (2011) Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20:3289–3303PubMedCrossRef Broeks A, Schmidt MK, Sherman ME et al (2011) Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 20:3289–3303PubMedCrossRef
35.
go back to reference Bertucci F, Orsetti B, Negre V et al (2008) Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27:5359–5372PubMedCrossRef Bertucci F, Orsetti B, Negre V et al (2008) Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27:5359–5372PubMedCrossRef
Metadata
Title
MUTYH gene variants and breast cancer in a Dutch case–control study
Authors
Astrid A. Out
Marijke Wasielewski
Petra E. A. Huijts
Ivonne J. H. M. van Minderhout
Jeanine J. Houwing-Duistermaat
Carli M. J. Tops
Maartje Nielsen
Caroline Seynaeve
Juul T. Wijnen
Martijn H. Breuning
Christi J. van Asperen
Mieke Schutte
Frederik J. Hes
Peter Devilee
Publication date
01-07-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-1965-0

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine